{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P07288",
      "entity_text" : "prostate-specific antigen",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-1224" ],
      "Organ" : [ "uberon:UBERON:0000479" ]
    }
  },
  "verbose_text" : "The majority of patients with advanced prostate cancer have an initial response to ADT; however, most patients develop castration resistant prostate cancer (CRPC), which is characterized by disease advancement with increasing levels of prostate specific antigen (PSA) and/or deterioration of symptoms despite anorchid testosterone (T) levels XREF_BIBR.",
  "reading_complete" : "2020-08-04T10:37:06Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:35:59Z",
  "trigger" : "levels",
  "evidence" : [ "levels of prostate-specific antigen" ],
  "pmc_id" : "3607121",
  "score" : 0
}